Drug Interactions With Risk of QT-prolongation in a General Hospital

Drug Interactions With Risk of QT-prolongation in a General Hospital: an Epidemiological Point Prevalence Study

In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.

Study design: epidemiological point prevalence study

Target population: Patients with haloperidol treatment

The following aspects will be investigated:

• The medication profiles will be checked for drug interactions with risk of QT-prolongation.
• Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected.
• Safety measurements (e.g. ECG) will be documented.

Inclusion Criteria:

• treatment with haloperidol (started in the hospital)

Exclusion Criteria:

• age < 18 years